Health Canada

Langan Model T15n Enhanced CO monitor has been used by Water and Air Quality Bureau to measure carbon monoxide levels across Canada. This table is a summary of carbon monoxide measured inside homes between 2007 and 2015 at 1 minute intervals (with the exception of Ottawa* which recorded every 5...

This dataset contains a list of formulants that are found in pest control products currently registered in Canada under the Pest Control Products Act and Regulations. This list is updated twice a year to reflect the addition of new formulants and the deletion of formulants no longer found in...

The Airborne Radionuclide Concentrations (ARC) Dataset is a general dataset of airborne radionuclide concentrations analyzed at the Radiation Protection Bureau (RPB). The RPB is responsible for delivering Health Canada’s program in the area of ionizing radiation protection. This dataset includes...

The Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS) is a biennial school-based survey of alcohol, cannabis, tobacco and drug use among Canadian students in grades 7 through 12. Data for the CSTADS 2021-2022 cycle were collected from more than 61,000 students between September 2021 and...

Health Canada's top priority is protecting the health and safety of Canadians. The department has a strong record of enhancing drug safety in Canada and is continually looking for ways to strengthen it.

Thousands of Canadians are turning to laser eye surgery to correct their vision and eliminate their dependency on glasses or contact lenses. Like all medical procedures, laser eye surgery provides benefits, but poses risks.

Acetaminophen is safe and effective when used as directed, but there is a limit to how much you can take in one day. Taking more than the recommended dose can cause severe or even fatal liver damage.

Educational module includes an outline of Vanessa’s Law, who/what/when of regulations for mandatory reporting of adverse drug reactions and medical device incidents, required data elements in reports.

Educational module includes considerations for mandatory reporting of adverse drug reactions and medical device incidents, reporting options to Health Canada, differentiating types of reactions, incidents and problems.

Educational module helps identify and overcome barriers to hospital mandatory reporting of adverse drug reactions and medical device incidents, recognize opportunities and describe strategies and systems.

Educational module provides overview of health product vigilance, report management, post-market surveillance activities and Health Canada risk communications.

This notice is being issued to clarify to drug manufacturers and sponsors that elements of Risk Management Plans (RMPs) required by Health Canada, such as controlled distribution programs, are not intended to restrict access to Canadian Reference Products (CRPs) for generic drug manufacturers for...

We are issuing this notice to help drug manufacturers and sponsors when preparing the Canadian-specific considerations and elements in the risk management plans (RMPs) for certain drug products. This notice describes what is required for certain drug products.

Health Canada’s Evolving Approach to Leveraging Real World Evidence (RWE) for Drug Regulatory Decisions.

This guidance document provides market authorization holders (MAHs) with assistance on how to comply with the Food and Drugs Act, the Food and Drug Regulations, and the Natural Health Products Regulations with respect to reporting adverse reactions (ARs) to marketed health products, but excluding...

Health Canada sets the standards for health product advertising material in Canada to help advertisers produce messages that are not false, misleading or deceptive.

Learn how Health Canada makes sure that the health products you use are safe, effective and of high quality.

Only health products that Health Canada authorizes for sale in Canada may be advertised. Specific requirements exist for advertisements of prescription drugs to consumers.

Health Canada has adopted and integrated the use of risk management plans (RMPs) and the International Conference on Harmonization (ICH) E2E Guideline into the regulatory review of drugs in Canada. A risk management plan (RMP) is a document that identifies and characterizes risks and...

Information on risk management plan submissions for drugs including when to file, considerations, requirements, and compliance.